{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=INT-747&page=2", "query": { "intervention": "INT-747", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=INT-747&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-14T12:09:23.744Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05223036", "title": "Testing Obeticholic Acid for Familial Adenomatous Polyposis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Attenuated Familial Adenomatous Polyposis", "Colorectal Carcinoma", "Duodenal Carcinoma", "Familial Adenomatous Polyposis" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Gastrointestinal Endoscopy", "type": "PROCEDURE" }, { "name": "Obeticholic Acid", "type": "BIOLOGICAL" }, { "name": "Placebo Administration", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2023-01-19", "completion_date": "2026-04-17", "has_results": false, "last_update_posted_date": "2026-05-14", "last_synced_at": "2026-09-14T12:09:23.744Z", "location_count": 6, "location_summary": "Scottsdale, Arizona • Kansas City, Kansas • Boston, Massachusetts + 3 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05223036" }, { "nct_id": "NCT05239468", "title": "Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Biliary Cholangitis" ], "interventions": [ { "name": "Bezafibrate 100 mg", "type": "DRUG" }, { "name": "Bezafibrate 200 mg", "type": "DRUG" }, { "name": "Obeticholic Acid 5 mg", "type": "DRUG" }, { "name": "Obeticholic Acid placebo", "type": "DRUG" }, { "name": "Bezafibrate Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Intercept Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2022-03-21", "completion_date": "2025-09-01", "has_results": true, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-09-14T12:09:23.744Z", "location_count": 17, "location_summary": "Birmingham, Alabama • Coronado, California • Mission Hills, California + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Coronado", "state": "California" }, { "city": "Mission Hills", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05239468" }, { "nct_id": "NCT00570765", "title": "Study of INT-747 as Monotherapy in Participants With Primary Biliary Cirrhosis (PBC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Liver Cirrhosis, Biliary" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Obeticholic Acid (OCA)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Intercept Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 60, "start_date": "2008-01-17", "completion_date": "2017-09-25", "has_results": true, "last_update_posted_date": "2021-06-22", "last_synced_at": "2026-09-14T12:09:23.744Z", "location_count": 4, "location_summary": "Detroit, Michigan • Houston, Texas • Richmond, Virginia + 1 more", "locations": [ { "city": "Detroit", "state": "Michigan" }, { "city": "Houston", "state": "Texas" }, { "city": "Richmond", "state": "Virginia" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00570765" }, { "nct_id": "NCT03439254", "title": "Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Compensated Cirrhosis", "Nonalcoholic Steatohepatitis" ], "interventions": [ { "name": "Obeticholic acid (10 mg)", "type": "DRUG" }, { "name": "Obeticholic acid (10 mg to 25 mg)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Intercept Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 919, "start_date": "2017-08-30", "completion_date": "2022-09-08", "has_results": true, "last_update_posted_date": "2023-10-23", "last_synced_at": "2026-09-14T12:09:23.744Z", "location_count": 120, "location_summary": "Dothan, Alabama • Madison, Alabama • Chandler, Arizona + 96 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Madison", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03439254" }, { "nct_id": "NCT06488911", "title": "To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and Bezafibrate", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Primary Biliary Cholangitis" ], "interventions": [ { "name": "FDC tablet (OCA 5 mg + BZF 400 mg SR)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Intercept Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2024-07-01", "completion_date": "2025-10-21", "has_results": true, "last_update_posted_date": "2026-06-08", "last_synced_at": "2026-09-14T12:09:23.744Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Coronado, California • Tampa, Florida + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Coronado", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT06488911" }, { "nct_id": "NCT04939051", "title": "Obeticholic Acid for Prevention in Barrett's Esophagus", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Barrett Esophagus", "Esophageal Adenocarcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Esophageal Biopsy", "type": "PROCEDURE" }, { "name": "Esophagogastroduodenoscopy", "type": "PROCEDURE" }, { "name": "Liver Ultrasonographic Elastography", "type": "PROCEDURE" }, { "name": "Obeticholic Acid", "type": "BIOLOGICAL" }, { "name": "Placebo Administration", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2024-01-03", "completion_date": "2027-09-01", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-09-14T12:09:23.744Z", "location_count": 8, "location_summary": "Kansas City, Kansas • Ann Arbor, Michigan • St Louis, Missouri + 2 more", "locations": [ { "city": "Kansas City", "state": "Kansas" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04939051" }, { "nct_id": "NCT00550862", "title": "Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Liver Cirrhosis, Biliary" ], "interventions": [ { "name": "INT-747", "type": "DRUG" }, { "name": "Ursodeoxycholic Acid (URSO)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Intercept Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 165, "start_date": "2007-10", "completion_date": "2010-12", "has_results": true, "last_update_posted_date": "2024-02-06", "last_synced_at": "2026-09-14T12:09:23.744Z", "location_count": 13, "location_summary": "Gainesville, Florida • Miami, Florida • Boston, Massachusetts + 9 more", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Novi", "state": "Michigan" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00550862" }, { "nct_id": "NCT01865812", "title": "Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Participants With Primary Biliary Cirrhosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Biliary Cirrhosis" ], "interventions": [ { "name": "Obeticholic Acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Intercept Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2013-12-03", "completion_date": "2016-09-12", "has_results": true, "last_update_posted_date": "2022-08-24", "last_synced_at": "2026-09-14T12:09:23.744Z", "location_count": 7, "location_summary": "La Jolla, California • Sacramento, California • Miami, Florida + 4 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01865812" }, { "nct_id": "NCT05133830", "title": "Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy Adult Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pruritus" ], "interventions": [ { "name": "Obeticholic acid", "type": "DRUG" }, { "name": "Linerixibat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 52, "start_date": "2021-11-23", "completion_date": "2022-05-31", "has_results": false, "last_update_posted_date": "2022-11-08", "last_synced_at": "2026-09-14T12:09:23.744Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05133830" }, { "nct_id": "NCT02548351", "title": "Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non Alcoholic Steatohepatitis (NASH)" ], "interventions": [ { "name": "Obeticholic Acid", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Intercept Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 2477, "start_date": "2015-09-22", "completion_date": "2023-09-15", "has_results": true, "last_update_posted_date": "2024-10-01", "last_synced_at": "2026-09-14T12:09:23.744Z", "location_count": 175, "location_summary": "Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 116 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02548351" } ] }